As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Medicare contractor Palmetto is proposing to expand coverage to ensure that more patients have access to genomic profiling when tissue-based testing is not possible.
Under the agreement, Bellwether researchers will join the team advancing Guardant's LUNAR early cancer detection and monitoring assays.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.